Fractyl Health's mission focuses on addressing the root causes of obesity and T2D, rather than merely managing the symptoms of these metabolic diseases.

This Rejuva platform employs adeno-associated virus (AAV) technology to develop gene therapies that specifically target the pancreas, aiming to provide effective treatments for obesity and type 2 diabetes (T2D).

Following the conference, Fractyl Health plans to submit a Clinical Trial Application (CTA) for their therapy RJVA-001, which targets T2D, with preliminary data anticipated in 2026.

Additional details regarding the presentation and the therapy will be made available on Fractyl's website after the conference concludes.

During the conference, Fractyl will deliver an oral presentation titled 'Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model,' which is scheduled for May 17, 2025.

Fractyl Health, Inc. is set to present preclinical data from its innovative Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform at the upcoming ASGCT 2025 Annual Meeting in New Orleans, scheduled for mid-May.